Progestin regulation of gene expression was assessed in the progestin-dependent murine tumor line C4HD which requires MPA, a synthetic progestin, for in vivo growth and expresses high levels of progesterone receptor (PR). By using suppressive subtractive hybridization, caveolin-1 was identified as a gene whose expression was increased with in vivo MPA treatment. By Northern and Western blot analysis, we further confirmed that caveolin-1 mRNA and protein expression increased in MPA-treated tumors as compared with untreated tumors. When primary cultures of C4HD cells were treated in vitro with MPA, caveolin-1 levels also increased, effect that was abolished by pre-treatment with progestin antagonist RU486. In addition, MPA promoted strong caveolin-1 promoter transcriptional activation both in mouse and human breast cancer cells. We also showed that MPA regulation of caveolin-1 expression involved in activation of two signaling pathways: MAPK and PI-3K. Short-term MPA treatment of C4HD cells led to tyrosine phosphorylation of caveolin-1 protein, where Src was the kinase involved. Additionally, we showed that MPA-induced association of caveolin-1 and PR, which was detected by coimmunoprecipitation and by confocal microscopy. Finally, we proved that MPA-induced proliferation of C4HD cells was inhibited by suppression of caveolin-1 expression with antisense oligodeoxynucleotides to caveolin-1 mRNA. Furthermore, we observed that inhibition of caveolin-1 expression abrogated PR capacity to induced luciferase activity from a progesterone response elementdriven reporter plasmid. Comprehensively, our results demonstrated for the first time that caveolin-1 expression is upregulated by progestin in breast cancer. We also demonstrated that caveolin-1 is a downstream effector of MPA that is partially responsible for the stimulation of growth of breast cancer cells.
Introduction
All life long progesterone governs a wide range of biological processes in many tissues, eliciting its effect mostly by interaction with the classical progesterone receptor (PR), a member of the nuclear receptor superfamily of ligand-dependent transcription factors. Particularly in the mammary gland, progesterone controls cell proliferation and differentiation (Lydon et al., 2000) . Several reports have proved that progesterone's proliferative signal is essential not only for normal mammary gland growth, but also for the high incidence of mammary tumors observed in women before menopause (Lange et al., 1999; Ismail et al., 2003) . In the last few years, progesterone involvement in enhancing mammary tumor susceptibility has been widely documented (Magnusson et al., 1999; Ross et al., 2000) . This point is of clinical significance since long-term use of progestins combined with oral contraceptives and post-menopausal hormone replacement therapy could eventually be considered harmful. In this sense, to better decipher progesterone action in mammary tumorigenesis, it is necessary to identify the molecular pathways mediating progesterone signal. Thus, the present study was aimed at contributing to a clear understanding of the mechanism mediating progestin-induced tumor progression. Firstly, we performed a suppressive subtractive hybridization (SSH) (Diatchenko et al., 1996) assay to identify genes whose expressions were induced by in vivo progestin treatment in breast cancer. For that purpose, we used murine mammary C4HD tumor from an experimental model of hormonal carcinogenesis in which the synthetic progestin medroxyprogesterone acetate (MPA)-induced mammary adenocarcinomas in female BALB/c mice (Balana et al., 1999 (Balana et al., , 2001 Labriola et al., 2003; Salatino et al., 2004) . C4HD tumor is from ductal origin, requires MPA administration for in vivo and in vitro growth, and expresses high PR levels. Among several isolated cDNA fragments that corresponded to MPA-upregulated genes, we identified a portion of caveolin-1 gene. Based on MPA's mitogenic role in this tumor model, our finding of progestin regulation of caveolin-1 resulted particularly interesting since its elevated expression had been previously associated with prostate and breast cancer progression and metastasis (Yang et al., , 2000 Thompson et al., 1999) . Caveolin-1, the primary structural component of caveolae, is a 22 kDa integral membrane protein implicated in a variety of cellular functions including transport of cholesterol and small molecules into the cell and signal transduction (Smart et al., 1999) . Caveolin-1 undergoes alternate initiation during translation to generate two isoforms, caveolin-1a and caveolin-1b, that differ in their N-terminal sequence but share the same C-terminus (Scherer et al., 1995) . Recently, the focus of caveolin studies shifted notably from the structural and functional context to the signaling transduction scenario. Caveolin-1 was first associated to tumor growth suppression and classified as a tumor suppressor gene (Koleske et al., 1995; Couet et al., 1997; Engelman et al., 1997) . Nevertheless, since those early reports many authors have contributed to the idea that caveolin-1 expression was associated to tumor growth and cancer progression (Mouraviev et al., 2002; Timme et al., 2003; Williams et al., 2005) . At present, despite controversy, the accepted hypothesis is that caveolin-1 function in tumor growth appears to be context-dependent.
Caveolae were originally identified as flask-shaped invaginations of the plasma membrane, although there are also flat shaped ones within the plane of the plasma membrane or can even appear as detached vesicles (Shaul and Anderson, 1998; Smart et al., 1999) . They abound in endothelia, muscle cells, adipocytes and epithelial cells. Caveolae are enriched in molecules that play pivotal roles in intracellular signal transduction such as G-protein-coupled receptors, G proteins, receptor tyrosine kinases, components of the Rasmitogen-activated protein (MAP), Src protein tyrosine kinases, protein kinase C and oxide nitric synthase (Smart et al., 1999) . As a consequence, caveolae function as preassembled signaling complexes to integrate signal transduction and represent a physical manifestation of cross talks. Interaction with and modulation by caveolin-1 have been shown in many signal transduction pathways, including those regulated by steroids receptors or tyrosine kinase receptors. Hence, caveolin-1 has been shown to associate and regulate activation of androgen receptor (AR) (Lu et al., 2001) , estrogen receptor (ER) (Schlegel et al., 1999 (Schlegel et al., , 2001 , epidermal growth factor receptor (Couet et al., 1997) and insulin receptor (Yamamoto et al., 1998) . Particularly, transcriptional activities of ER and AR have been shown to be potentiated by caveolin-1 (Lu et al., 2001; Schlegel et al., 2001) . Even though caveolin-1 interaction with many of the signal transduction components is thought to have important consequences for cellular transformation; the role of caveolin-1 in cancer still remains controversial.
As MPA is the proliferative stimulus in C4HD cells and since we found that caveolin-1 is a progestin responsive gene in breast cancer, the aim of this work was to investigate how caveolin-1 expression is regulated by progestin, and to address whether caveolin-1 might play a role in the scenario of progestin-induced growth of breast cancer. Our results clearly showed that caveolin-1 expression is upregulated by progestin treatment in breast cancer both in vivo and in vitro. Furthermore, we provided evidence indicating that PI-3K and MAPK pathways are involved in caveolin-1 upregulation by MPA treatment. We also showed that short-term progestin treatment induced both Srcmediated phosphorylation of caveolin-1 and caveolin-1/PR physical association. Finally, we demonstrated that caveolin-1 is a downstream effector of MPA at least in part responsible for the growth stimulation of C4HD breast cancer cells.
Results
MPA is able to upregulate caveolin-1 expression both in vivo and in vitro C4HD tumor line was selected from this experimental model to study MPA regulation of gene expression in in vivo growth because it has exhaustively been characterized as regards to its proliferative behavior and response to MPA. C4HD tumors are not able to grow in absence of MPA treatment, express PR and ER, and display an exquisite sensitivity to MPA proliferative effect (Kordon et al., 1990) . Using suppressive subtractive hybridization (Diatchenko et al., 1996) , we compared mRNA populations from C4HD tumors of MPA-treated and untreated mice to obtain clones expressed in one population but not in the other. First, both mRNA populations were converted into cDNA and hybridized with each other. Unhybridized cDNAs, that represent genes differentially expressed, were cloned and colonies were identified by comparing spots between hybridization with labeled cDNA from MPA-treated and untreated tumors. By selectively amplifying by polymerase chain reaction (PCR) these differentially expressed sequences, we obtained nine non-redundant clones which represent genes whose expression was increased by MPA treatment. The cDNA inserts from these nine original clones were sequenced and analysed for identity. Interestingly, among the fragments isolated, a 274 bp fragment resulted similar to mouse caveolin-1 cDNA. Analysis with BLAST program revealed that the PCR fragment isolated was 99% identical over 274 bases to the 3 0 end of the mouse caveolin-1 isoform a mRNA (Figure 1a ) (Kogo and Fujimoto, 2000) and 89% identical over 92 bases to the human caveolin-1 mRNA (Glenney, 1992), but was not similar to the mouse or human caveolin-2 or caveolin-3 genes (Scherer et al., 1996; Way and Parton, 1996) (data not shown). PCR product corresponding to caveolin-1 was labeled and used as probe for Northern blot analysis to screen an extended panel of C4HD MPA-treated and untreated tumors from four different animals ( Figure 1b) . In every case, increased levels of caveolin mRNA were found in the MPA-treated tumor with respect to the untreated one (overall of five-fold increase). Interestingly, caveolin-1 mRNA was also detected in the hormoneindependent variant C4HI with levels similar to those observed in C4HD tumors growing in MPA-treated mice (Figure 1b , second lane). C4HI tumors do not require MPA administration for in vivo growth, but retain PR expression. To evaluate caveolin-1 expression at protein level, tumors from MPA-treated and untreated mice were excised, protein lysates were performed and caveolin expression was studied by Western blot. An overall of four-to five-fold increase in caveolin-1 a and b isoform expression was found in C4HD tumors from MPA-treated mice as compared to tumors from the untreated animals ( Figure 1c ). This increment was significant and reproducible. In the analysis, Figure 1 MPA upregulates caveolin-1 expression. (a) Clone 15-1 þ identity. Shown is the cDNA sequence identity corresponding to clone 15-1 þ obtained with BLAST program. The fragment analysed resulted 99% identical over 274 bases to the 3 0 end of the mouse caveolin-1 isoform a mRNA. (b) Caveolin-1 mRNA level. Forty mg of total RNA from 4 MPA-treated and 4 untreated hormonedependent C4HD tumors were loaded onto a 1% formaldehyde-agarose gel, electrophoresed and transferred to a nylon membrane. Total RNA from hormone-independent C4HI tumor was also included. Total RNA from liver was used as a negative control tissue. Amplified cDNA insert corresponding to caveolin-1 was random-labeled with [ 32 P] dCTP and used as probe. Caveolin-1 appears as a major mRNA form of about 2.5 kb. GAPDH mRNA was used for normalization. (c) Caveolin-1 protein expression in C4HD and C4HI tumors. Protein extracts (50 mg) from MPA-treated or -untreated C4HD tumors, and from C4HI tumors were subjected to Western blot analysis with an antibody to caveolin-1, isoforms a and b, or actin as loading control. (d) Caveolin-1 protein expression in C4HD primary culture cells. Primary cultures of C4HD cells were incubated for 48 h in medium with 0.1% ChFCS supplemented with 10 nM MPA or 10 nM MPA þ 10 nM RU486. A total of 25 mg protein from C4HD cell lysates were electrophoresed and immunoblotted with an anti-a and -b caveolin-1 antibody and an anti-actin antibody. (e) Caveolin-1 secretion in response to MPA. Conditioned media were collected after incubation of C4HD cells with 0.1%ChFCS or 0.1%ChFCS þ 10 nM MPA for 24 or 48 h and concentrated as described in 'Materials and methods'. The concentration product was subjected to Western blot analysis with an antibody to caveolin-1 (upper panel). The amount of caveolin-1 detected in cells lysates is shown in the lower panel. Experiments shown in (b) to (c) are representative of a total of four.
Progestin regulation of caveolin-1 expression M Salatino et al we included the hormone-independent C4HI tumor ( Figure 1c) , which in the absence of MPA, showed an expression of caveolin as elevated as that of C4HD tumor growing in MPA-treated animals.
MPA treatment of C4HD primary culture cells also resulted in increased caveolin-1 expression (Figure 1d ). This increment was abolished by pre-treatment with progestin antagonist RU486, indicating that the classical PR is involved in caveolin-1 induction. We next investigated the possibility of caveolin-1 being secreted by C4HD breast cancer cells into the culture media. Caveolin-1 was detected in conditioned media from C4HD cells. As can be observed in Figure 1e , the amount of caveolin-1 secreted correlated with the amount detected in cells lysates after 24 and 48 h of MPA-treatment.
Transcriptional activation of caveolin-1 promoter by MPA To determine whether upregulation of caveolin-1 protein by MPA occurs at the level of transcriptional regulation, we transiently transfected C4HD cells with a luciferase reporter vector under the transcriptional control of the mouse caveolin-1 promoter, PGL3-mcav-1-Luc. The relative activity of caveolin-1 promoter was increased more than two-fold by 48 h MPA treatment of C4HD cells (Figure 2a ). This activity was blocked by the addition of RU486, indicating that upregulation of caveolin-1 by MPA is mediated by the classical PR. Similar experiments were conducted in human breast cancer T47D cells which do not express caveolin-1, as shown by others (Trouet et al., 1999) and by our own experiments (data not shown). On T47D cells, progesterone has biphasic effects: stimulating growth first (0-24 h) and then inhibiting it (24-48 h) (Lange et al., 1999) . T47D cells were transiently transfected with the PGL3-mcav-1-Luc plasmid and treated for 24 h with MPA to promote progesterone-induced proliferation (data not shown). The relative activity of cav-1 promoter was increased up to 3.2-fold by MPA in T47D cells (Figure 2b ). This activity was also blocked by the addition of RU486, further indicating that PR plays a role in MPA ability to upregulate caveolin-1 expression (Figure 2b ).
To further demonstrate PR involvement in MPAinduced transcriptional activation of caveolin-1 promoter, we used human PR null T47D-Y cells (Lange et al., 1998) and mouse metastatic mammary tumor line LM3 which also lacks PR expression (Puricelli et al., 2002) . When these cell lines were transfected with PGL3-mcav-1-Luc vector, MPA treatment did not induce luciferase activity (Figure 2c and d) . However, when cells were cotransfected with human PRB, MPA strongly induced luciferase activity. Furthermore, RU486 inhibited this MPA-induced luciferase activity confirming the specificity of the effect (Figure 2c and d ). There were no detectable activation of a PGL3-basic promoterless vector in any of the cell lines used (first two bars in each graph).
MPA induced caveolin-1 Tyr 14 phosphorylation by a mechanism involving Src Although it is known that caveolin-1 isoform a is capable of being phosphorylated in tyr 14, its regulation and functional consequences are poorly understood. The requirement of Src activity for caveolin-1 activation has already been acknowledged (Li et al., 1996; Lee et al., 2000; Volonte et al., 2001) . In addition, accumulating data (Migliaccio et al., 1998; Castoria et al., 1999; Boonyaratanakornkit et al., 2001; Ballare et al., 2003) , including our own findings (Proietti et al., 2005) , have evidenced progestins ability to induce c-Src phosphorylation by a nongenomic mechanism in mammary tumor cells. Thus, we have recently shown that MPA treatment of C4HD cells for 2-5 min induced strong c-Src tyrosine phosphorylation, which was significantly inhibited by the selective Src kinase family inhibitor PP2 (Proietti et al., 2005) . These results prompted us to test whether MPA was able to induce caveolin-1 phosphorylation and whether Src was the protein kinase involved. As shown in Figure 3a and b, MPA-treatment for 5 and 10 min induced caveolin-1 phosphorylation in C4HD cells, as detected with a specific antibody for the tyr 14 phosphorylated form. Pre-treatment of C4HD cells with 10 nM of RU486 ( Figure 3a) or with 10 mM PP2 (Figure 3b ) prevented MPA-induced caveolin-1 phosphorylation, suggesting that both PR and Src kinase might be participating in this effect. The time-course of the phosphorylation process supported this idea, since Src is phosphorylated after 2 min treatment of MPA, while caveolin is phosphorylated after 5 min of MPA stimulation.
We then investigated whether activated Src could phosphorylate caveolin-1 in vitro. For this purpose, we immunoprecipitated Src from protein extracts of C4HD cells treated or untreated with MPA for 5 min, and from C4HD cells in which Src activation by MPA had been blocked by preincubation with PP2. We also immunoprecipitated caveolin-1 from C4HD cells growing in 0.1% ChFCS, and used it as a source of unphosphorylated caveolin-1 in the assay. As shown in Figure 3b , neither caveolin-1 nor Src obtained from C4HD cells not stimulated with MPA, were phosphorylated. Incubation of Src, immunoprecipitated from C4HD cells treated with MPA, with the unphosphorylated caveolin-1 in a reaction containing cold ATP, induced phosphorylation of caveolin-1 at tyrosine 14 residue. Neither inactive Src, obtained from C4HD cells growing in 0.1% ChFCS, nor Src inactivated by PP2-induced caveolin-1 phosphorylation (Figure 3c ). Taken together these results indicate that MPA induce shortterm phosphorylation of caveolin-1 and that Src is the tyrosine kinase involved in this effect.
MPA promotes caveolin-1 and PR physical association While caveolin-1 has been found to be physically associated with several members of the steroid receptor superfamily, association between PR and caveolin-1 has not been reported. In this work, we assessed caveolin-1 and PR physical interaction by performing coimmuno-precipitacion studies. C4HD cells were maintained in hormone-free medium for 72 h before MPA stimulation for 5, 10 and 30 min. Cell lysates were collected for immunoprecipitation with antibodies against caveolin, against PR, or with mouse or rabbit IgG. As shown in Figure 4a , when protein extracts were immunoprecipitated with PR antibody, caveolin-1 was clearly detected in immunoblots after 5 or 10 min treatment of MPA. Interaction between caveolin-1 and PR was also detected when the immunoprecipitation-immunoblotting procedure was reversed (Figure 4b ). Neither PR nor caveolin-1 was detected in immuno-complexes from rabbit or mouse IgG immunoprecipitations, demonstrating the specificity of the interaction. As we observed that caveolin-1 phosphorylation was induced after 5 and 10 min of MPA treatment ( Figure 3 ) and that association between PR and caveolin-1 displayed similar time courses, we explored whether caveolin-1 phosphorylation status could influence this interaction. To that end, coimmunoprecipitation assay was performed with C4HD cells treated or untreated with Src inhibitor PP2 before short-term MPA stimulation. As observed in Progestin regulation of caveolin-1 expression M Salatino et al Figure 4c , association between PR and caveolin-1 was not affected by blocking Src activation with PP2. We also used a specific p-cav-1 immunoprecipitating antibody but, once again, no association with PR was detected (data not shown) indicating that caveolin-1 phosphorylation was not a requirement for PR association. Further support for the existence of an association between PR and caveolin-1 in intact C4HD cells was provided by immunofluorescence confocal microscopy. C4HD cells growing in 0.1% ChFCS were cultured in absence or presence of MPA as described in Figure 4a and b. As can be seen in Figure 4d , in absence of MPA both caveolin-1 and PR are localized diffusely in the cytoplasm with no apparent signs of colocalization. However, after 5 or 10 min of MPA treatment, a specific and inducible colocalization is observed in the cytoplasm. After 30 min of MPA treatment, colocalization was no longer detectable (data not shown). These data support the findings obtained through the coimmunoprecipitation approach. As observed, there is a significant though modest colocalization of PR and caveolin-1 detected with both immunoprecipitation and immunofluorescence approaches. Comprehensively, these results indicate that MPA is able to rapidly induce association between a small pool of the total PR and caveolin-1 in C4HD murine breast cancer cells. , and then treated with MPA. Twenty-five mg protein from cell lysates was electrophoresed and Western blots were performed with anti-phosphocaveolin-1 or anti-phosphotyrosine c-Src antibodies as indicated. Membranes were then stripped and hybridized with anti-caveolin-1 and anti-Src antibodies. These experiments were repeated three times with similar results. (c) C4HD cells growing in 0.1% ChFCS were treated with MPA for 5 min, left untreated or preincubated for 90 min with PP2 before MPA stimulation. Cells were lysed and Src was immunoprecipitated from 500 mg protein extracts from each treatment. Unphosphorylated caveolin-1 was immunoprecitated from 500 mg protein extract from C4HD cells growing in 0.1%ChFCS. The immunoprecipitated caveolin-1 was then subjected to a cold in vitro phosphorylation assay as described in 'Materials and methods'. Proteins were separated by electrophoresis, gels were transferred onto nitrocellulose and in the lower part of the gels, immunoblots were performed with the anti-phospho caveolin-1 Tyr 14 antibody. The filter was stripped and reprobed with an anti caveolin-1 antibody. The upper part of the gel was revealed with an anti-phospho Src antibody. The filter was stripped and hybridized with an antibody anti-total Src. As specificity control, 500 mg protein extract from C4HD cells treated for 5 min with MPA were immunoprecipitated with IgG rabbit and subjected to the same in vitro phosphorylation protocol (last lane of each panel). This experiment was repeated three times with same results. W: Western Blot, IP: immunoprecipitation.
Progestin regulation of caveolin-1 expression M Salatino et al MAPK and PI-3K pathways are both required for MPA to induce caveolin-1 expression in C4HD cells We next examined the signaling pathways that govern MPA-induced caveolin-1 gene expression. We have already shown that in C4HD cells, MPA induces both Akt and p42/44 MAPK phosphorylation (Salatino et al., 2004) , hence we wondered if activation of these signaling pathway was required for MPA-induced caveolin-1 expression. To assess the requirement of p42/44 MAPK and PI-3K activation, we decided to alternatively block these two pathways with specific inhibitors. As shown in Figure 5a (first panel), blockage of PI-3K activation with LY294002 resulted in inhibition of MPA-induced caveolin expression. As control, we showed that Akt phosphorylation at residue ser-473 analysed with a specific antibody was prevented when C4HD cells were pre-treated with LY294002 (third panel). We also evaluated MAPK pathway involvement in MPA-induced caveolin upregulation. Inhibition of MAPK activation, using the selective MEK1/MAPK inhibitor U0126, was sufficient to eliminate MPAcapacity to induce caveolin-1 expression ( Figure 5b ). As expected, complete inhibition of MAPK activation was observed when C4HD cells were pre-treated with U0126 in the presence of MPA (third panel). To assess the involvement of these pathways in genomic functions of PR on the caveolin-1 promoter, we used the reporter vector PGL3-mcav-1-Luc previously described in Figure 2. C4HD, T47D and LM3 cells were transiently transfected cells with the caveolin-1 promoter reporter vector, and in the case of PR negative LM3 cells we also transfected with hPRB vector. Caveolin-1 promoter luciferase activity was assessed after treating cells with the specific signaling pathway inhibitors plus MPA, as described above. Pre-treatment of C4HD, T47D and LM3 cells with LY294002 or with U0126 prevented Figure 4 MPA induces caveolin-1 association with PR. (a) Coimmunoprecipitation assay: C4HD cells were treated with MPA 10 nM for the indicated times, and PR was immunoprecipitated from 500 mg protein extracts. As control, lysates were also immunoprecipitated with normal mouse serum (NMS, second lane). Immunocomplexes were subjected to SDS-PAGE and analysed by Western blotting with a caveolin-1 antibody (upper panel). Twenty mg protein from cell extracts were directly immunoblotted with the caveolin-1 antibody (first lane, upper panel). Identical aliquots of each immunoprecipitate were subjected to immunoblot analysis with anti-PR antibody to verify that nearly equal amount of immunoprecipitated proteins were loaded (lower panel).
(b) Coimmunoprecipitation process was reversed using caveolin-1 to precipitate PR. (c) C4HD cells were treated with MPA 10 nM for the indicated times or pretreated with the selective Src kinase family inhibitor PP2. Coimmunoprecipitation process was performed using caveolin-1 to precipitate PR. Immunocomplexes were subjected to SDS-PAGE and analysed by Western blotting with an anti-PR antibody (upper panel). Identical aliquots of each immunoprecipitate were subjected to immunoblot analysis with caveolin-1 antibody. Twenty mg protein from cell extracts were directly immunoblotted with the p-src antibody (lower panel) to verify PP2 effciency, membranes were then stripped and incubated with src antibody. This is a representative experiment out of a total of three. (c) Immunofluorescence and confocal microscopy: C4HD cells were incubated in 0.1% ChFCS with MPA 10 nM for 5 or 10 min or left untreated and then fixed. Caveolin-1 (green) and PR (red) were detected as described in 'Materials and methods'. Same cells are shown in each row and images on the right panel are formed by superimpositions of the other two panels in the same row. MPA-induced colocalization of caveolin-1 and PR is denoted by yellow colour. The nuclei of C4HD cells were stained with DAPI. Images shown here are representatives of three experiments Â 100 magnification.
Progestin regulation of caveolin-1 expression M Salatino et al MPA-induced luciferase activity driven by caveolin-1 promoter (Figure 5c ), clearly indicating that both PI-3K and MAPK were necessary to activate caveolin-1 promoter by MPA. Neither LY294002 nor U0126 affected the viability of C4HD cells as demonstrated by trypan blue exclusion analysis (data not shown). Jointly considered, these results indicate that MPA regulation of caveolin-1 expression involves activation of at least two endogenous signaling pathways: MAPK and PI-3K.
Caveolin-1 is involved in MPA-induced proliferation and PR activation As MPA induces C4HD cell proliferation and caveolin-1 expression, we wondered whether caveolin-1 was involved in MPA proliferative effects. To address this question, we treated C4HD cells with an antisense oligodeoxinucleotide (ASODN) complementary to the 15-base initiation sequence of mouse caveolin-1 mRNA, to modulate the intracellular caveolin-1 level. As shown (Figure 6a ), MPA-induced caveolin-1 expression was dose-dependently reduced by ASODN treatment in C4HD cells. At 2 mM of ASODN treatment, we achieved the highest expression inhibition (64.7%) with respect to C4HD cells growing in MPA alone ( Figure 6a ). As control, we used a scramble ODN (SODN) which had no effect on caveolin-1 expression, confirming the specificity of the antisense suppression. As a consequence of the suppression of caveolin-1 upregulation by MPA, the proliferative activity induced by MPA on C4HD cells was significant and dose-dependently reduced ( Figure 6b ). We lastly evaluated whether blockage of caveolin-1 expression could interfere with PR transcriptional activation both in mouse and human breast cancer cells. Thus, C4HD cells were transiently transfected with a MMTV-Luc reporter vector, containing five PREs upstream of the luciferase reporter gene, treated with 2 mM ASODN or SODN to caveolin-1 and stimulated with MPA for 48 h. As expected, treatment of C4HD cells with MPA strongly induced the activation of PRE-Luc reporter construct. However, when caveolin-1 expression was inhibited by ASODN treatment, MPA-induced activation of luciferase activity was (Figure 6d ), further confirming that caveolin-1 was necessary to full trancriptional activation of PR. Finally as observed in Figure 6e , overexpression of caveolin-1 in human T47D cells significantly increased MPA-induced activation of the PRE-driven luciferase reporter vector from two-fold in caveolin negative cells to five-fold in caveolin-1 positive cells. As glucocorticoid receptor (GR) and androgen receptor (AR) bind to the same response element as PR, it is worth pointing out that C4HD cells express neither GR nor AR (Montecchia et al., 1999) . This result indicates that caveolin-1 protein is required to achieve a fully transcriptional PR activation in C4HD cells.
Caveolin-1 is not mutated at P132 residue A recent mutational analysis performed in human breast carcinomas has identified in 16% of the cases a specific point mutation of the caveolin-1 gene at codon 132 (Hayashi et al., 2001 ), a highly conserved proline residue located in the membrane spanning domain . NIH 3T3 cells stably overexpressing the same caveolin-1 mutant (P132L) displayed increased proliferative and invasive phenotype resulting in a mutant driving cell transformation (Lee et al., 2002) . This led us to evaluate the possibility that caveolin-1 in C4HD tumor might be mutated in proline 132 contributing to its transforming role. We used PCR-RFLP mutational screening, in view of the fact that there was not a proper enzymatic site in the target region, we designed a mismatch primer that will generate a KpN-1 restriction site only if caveolin-1 was wild-type. As seen in Figure 7a , Proline at position 132 is highly conserved between human and mouse, being codified by the codon ccg in mouse. Mismatch primer generated a KpN-1 restriction site (ggtacc) in case of wild-type caveolin-1 sequence. The mutation P132L eliminates KpN-1 restriction site, giving rise to a rapid method of screening the specific P132L mutation in mouse. After purifying genomic DNAs derived from C4HD tumor samples, C4HD cells and lymphocytes we amplified caveolin-1 fragments using the specific primers (mismatch and reverse, see 'Materials and Methods') and performed PCR-RFLP assay. As shown in Figure 7b amplified control lymphocytes genomic DNA digested with KpN-1, released a fragment of 24 bases, resulting in a fragment of 165 (cut) bases instead (Figure 7c ). Both C4HD tumor and C4HD cells evidenced a wild-type sequence around 132 codon which was similar to control lymphocytes. Furthermore, a fragment of 355 bases corresponding to caveolin-1 exon 3 was analysed ), but we were unable to detect any mutation as compare to previously published mouse caveolin-1 sequence (data not shown).
Discussion
In the present work, we have for the first time demonstrated that caveolin-1 is a progesterone-responsive gene in breast cancer. We identified caveolin-1 as a gene whose expression was upregulated both in vivo and in vitro by MPA in an experimental model of hormonal carcinogenesis in which the synthetic progestin MPA, induced mammary tumors in female BALB/c mice. We showed that in vitro induction of caveolin-1 expression by MPA was fully dependent on PR activation, since blockage of PR activity by antiprogestin RU486 completely abrogated MPA capacity to induce caveolin-1 expression. Hormonal regulation of caveolin-1 expression has already been reported in cancer cells. Testosterone was found to induce caveolin-1 protein expression in mouse and human prostate cancer cell lines (148-1PA, ABAC3 and LNCaP) (Pflug et al., 1999; Li et al., 2001) . Estrogens (E 2 ) were capable of modulating caveolin-1 protein expression in breast MCF-7 cells and in VSMC (vascular smooth muscle cells) through the transcriptional regulation of caveolin-1 promoter and the modulation of protein degradation (Razandi et al., 2002) . Nevertheless, this is the first report of progesterone regulation of caveolin-1 expression in breast cancer cells. We have also shown that caveolin-1 is secreted by C4HD cancer cells, suggesting that it could function as a paracrine/autocrine factor. Moreover, there was a positive correlation between the amounts of caveolin-1 detected in cell lysates and the ones secreted to the media. Further experiments are required to determine whether secreted caveolin-1 has any biological activity in progestin-induced breast cancer. Thompson and coworkers (Tahir et al., 2001 ) have detected caveolin-1 in conditioned media from androgen-insensitive mouse and human prostate cancer cells in variable amounts. They observed that while nonprostatic cells such us endothelial, fibroblast and smooth muscle had a substantial amount of intracellular caveolin-1 they were not able to secrete it into the conditioned media. Additionally, they evaluated the function of secreted caveolin-1 and proposed that it was capable of promoting cell viability and clonal growth, and of preventing apoptosis of adjacent caveolin-1 negative prostate cancer cells. They also specifically detected higher levels of caveolin-1 in the serum of prostate cancer patients as compared with the serum of normal individuals, raising the possibility of using caveolin-1 as a therapeutic target. We have also demonstrated that MPA-induced caveolin-1 expression was induced at the level of transcriptional activation through a progesterone-dependent receptor mechanism, not only in murine cancer cells but also in human breast cancer cells. MPAinduced caveolin-1 promoter activation was abrogated by pretreatment with progestin antagonist RU486 in C4HD cells, in caveolin-1 null/PR positive T47D cells and in reconstitution experiments using PR null T47D-Y or LM3 cells cotransfected with the caveolin-1 promoter-containing reporter gene and hPRB, clearly indicating PR-dependence of the effect. These findings are supported by the existence of a PRE hemi-site in the caveolin promoter sequence, as indicated by computational analysis using the MatInspector program. Our results are in agreement with a recent study which through gene profiling has demonstrated that 5 days of progesterone treatment induced caveolin-1 expression at mRNA level (Syed et al., 2005) in ovarian cancer cells (OVAC). Hormonal specificity was also demonstrated with RU486, further supporting our own results.
Caveolin-1 was first discovered as a tyrosine-phosphorylated protein in Rous sarcoma virus-transformed fibroblasts (Glenney, 1989) . Back then, even when the function of caveolin-1 was totally unclear, a sound correlation was found between transformation and its tyrosine phosphorylation. Here, we have shown that MPA was able to induce caveolin-1 phosphorylation at tyr 14 in C4HD breast cancer cells. We also observed that this phosphorylation was prevented by pretreatment with the Src kinase inhibitor PP2 or by antiprogestin RU486, indicating that activity of both PR and Src were essential to achieve MPA-induced Tyr phosphorylation of caveolin-1. Src-mediated in vitro phosphorylation of endogenous caveolin-1 on tyrosine 14 also has been demonstrated in NIH 3T3 cells, after stimulation with a variety of cellular stressors (i.e. high osmolarity, H 2 O 2 and UV light) (Volonte et al., 2001) , in v-Src transformed NIH 3T3 cells (Li et al., 1996) and in uterine smooth muscle cells after E 2 treatment (Kiss et al., 2005) but ours is the first report demonstrating that caveolin-1 can be rapidly phosphorylated in response to progestins. We also have demonstrated the existence of an interaction between caveolin-1 and PR by coimmunoprecipitacion studies and by immunofluorescence and confocal microscopy. MPA was able to induce rapid and transient PR and caveolin-1 association in C4HD murine breast cancer cells. We further demonstrated that Src-induced caveolin-1 phosphorylation was not a requirement for caveolin-1/PR physical association, which enable us to hypothesize that the formation of caveolin-1/PR heteromeric complex is independent of Src activity. The modest colocalization detected between PR and caveolin-1 detected could be explained by the fact that that pool of PR around the plasma membrane is modest, like often occurs with other steroid receptors (Watson and Gametchu, 2003) , decreasing the possibility of an encounter between PR and caveolin-1 which is preferentially located in subdomains within plasma membrane. Another possibility is that a fraction of caveolin-1 can shuttle in and out from plasma membrane to the cytosol (Anderson, 1998) ; in this case association would be possible between the scant pool of PR and caveolin-1 that colocalized in the cytosol. Previous reports have demonstrated that caveolin-1 can interact with other steroid receptors such as ER (Schlegel et al., 1999) and AR (Lu et al., 2001 ), but interaction with PR had so far never been observed. Recombinant caveolin-1 was shown to positively regulate ERa-mediated signal transduction in MCF-7 mammary epithelial cells (Schlegel et al., 1999) through physical interaction. Regarding AR, association between caveolin-1 and this steroid receptor was shown to be an androgen-dependent process, providing evidence for a physiological role of this interaction (Lu et al., 2001) . Thus far, we have not able to elucidate the role played by the PR/caveolin-1 transient heteromeric complex. We could then hypothesized that upon MPA stimulation, PR and caveolin-1 association contribute to rapidly activate MPA-driven phosphorylations, such as p-src (Proietti et al., 2005) which in turn phosphorylates caveolin-1, these speculations are supported by the fact Ru486 completely blocked MPA-capacity to induce psrc-mediated caveolin-1 phosphorylation (Figure 3a) . The mechanism that determines PR and caveolin-1 functional interaction deserves further investigations.
The mechanisms that govern caveolin-1 expression had so far remained unknown. An additional novel finding of this work is that MPA regulation of caveolin-1 expression requires activation of PI-3K/Akt and p42/44 MAPK pathways. We have previously demonstrated that C4HD tumors growing in MPA-treated mice have fully activated PI-3K/Akt and p42/44MAPK pathways (Salatino et al., 2004) . Our present findings evidenced that blockage of PI-3K or p42/44MAPK pathways using specific inhibitors such us LY294002 and U0126, respectively, resulted in complete abrogation of MPA capacity to upregulate caveolin-1 expression at both protein and transcriptional level. Thompson and coworkers (1999) have previously reported that overexpression of caveolin-1 in non-expressing LNCaP prostate cancer cells led to increased levels of phosphorylated Akt and of multiple Akt downstream targets (Li et al., 2003) , linking PI-3K/Akt cascade with caveolin-1. Said study also indicates that a positive regulation of PI-3K/ Akt pathway by caveolin-1 determines survival of prostate cancer cells. Thus, caveolin-1 involvement in PI-3K/Akt pathway activation has been proved, but ours is the first report indicating that Akt activation is required to induce caveolin-1 expression. The facts that caveolin-1 can activate PI-3K pathway (Li et al., 2003) , as demonstrated in prostate cancer cells, and that caveolin-1 expression is directly regulated by activation of the PI-3K cascade in breast cancer cells, suggest a positive reciprocal regulation, which could mean that caveolin is both upstream and downstream of this signaling pathway. MAPK pathway was also previously linked to caveolin-1 in several ways. On one hand, caveolin-1 protein functioned as a negative regulator of this pathway, as reported in NIH 3T3 oncogenictransformed cells (Engelman et al., 1997) . On the other, caveolin-1 expression was negatively regulated by activation of the p42/44 MAPK pathway, and restored by pre-treatment with a MEK inhibitor (PD98059) in the same artificially transformed cells (Engelman et al., 1998 . Although these results are opposed to ours, they support our idea that p42/44 MAPK pathway is relevant to regulate caveolin-1 expression possibly by regulating the transcription factors activity that binds to caveolin-1 promoter or even by regulating PR activity itself.
We next assessed the role of caveolin-1 in MPAinduced proliferation in mouse breast cancer cells. Our results demonstrated that inhibition of caveolin-1 expression by using an antisense strategy abolished MPA-induced C4HD cell proliferation. This suggested that caveolin-1 is a downstream effector of MPA in part responsible for MPA-induced growth stimulation of C4HD breast cancer cells. In ABAC3 prostate cancer cells, transfection with a vector encoding an antisense to caveolin-1 has been shown to significantly inhibit the effects of testosterone on cell survival and clonal growth , demonstrating that caveolin-1 was involved in androgen-induced cancer growth. Unlike the former, in OVAC ovarian cancer cells, progesterone was shown to induce caveolin-1 expression, and ectopic expression of caveolin-1 was shown to cause growth inhibition (Syed et al., 2005) , which is in agreement with the protective role that progesterone has in ovarian cancer (Ho, 2003) . It is not yet clear why progesteroneinduced caveolin-1 has opposite effects as regards cell proliferation in OVAC ovarian and in C4HD breast cancer cells. Caveolin-1 was at first associated to tumor growth suppression and classified as a tumor suppressor gene (Koleske et al., 1995; Couet et al., 1997) . Nevertheless, since those first reports many authors, included ourselves, have contributed to the idea that caveolin-1 expression is actually associated to tumor growth and cancer progression. At present, in spite of the controversy, there is an agreement on the hypothesis that caveolin-1 function in tumor growth appears to be context-dependent. Antagonism of caveolin-1 actions in ovarian and breast cancer cell proliferation could be a further example of this context-dependent role.
In an attempt to determine why caveolin-1 downregulation inhibited MPA-induced proliferation, we evaluated PR transcriptional activity after caveolin-1 ASODN treatment. When caveolin-1 expression was reduced in the mouse progestin dependent C4HD line, as well as in the high metastatic PR negative LM3 line, we observed that both endogenous PR and transfected hPR were transcriptionally less potent. On the contrary when caveolin-1 was overexpressed in negative T47D human breast cancer cells, MPA-induced PR transcriptional activity was enhanced. Both experimental approaches led us to reason out that caveolin-1 is contributing to the activation of PR activity. At this point, we cannot yet define the relationship between caveolin-1 and PR transcriptional activation, but we can hypothesize that caveolin-1 could facilitate PR phosphorylation/dephosphorylation in those sites required for transcriptional activity, by contacting the proper serine/threonine kinases or phosphatases. As PR is a phosphoprotein with active regulation of its phosphorylation status, and since many signal pathways implicated in PR transactivation such as MAPK (Labriola et al., 2003) and EGFR (Couet et al., 1997) are situated in caveolae, it is reasonable to predict that PR/caveolin-1 interaction may facilitate PR phosphorylation process.
Multiples lines of evidences demonstrate that caveolin-1 is also involved in intracellular trafficking, forming complexes with chaperons involved in steroid hormone receptor nuclear translocation. Moreover, functional interaction of caveolin-1 with steroid receptors may be part of a general mechanism of its regulation since caveolin-1 has been shown to potentiate transactivation of ER-a (Schlegel et al., 1999) and activation and nuclear translocation of phosphorylated AR (Li et al., , 2003 Lu et al., 2001; Mouraviev et al., 2002) , as mentioned before. Preliminary results obtained in our lab using immunofluorescence and confocal microscopy indicated, as occurs with the AR, that caveolin-1 could be participating in liganded PR nuclear translocation, both in C4HD and T47D transfected with caveolin-1 cells (data not shown). We are currently working on this exciting hypothesis.
Based upon these experimental pieces of evidences, we can propose a positive feed-back model where MPA is transcriptionally upregulating caveolin-1 expression through its own receptor, regulation which requires the activation of MAPK and PI-3K/Akt pathways; as previously discussed, this newly synthesized caveolin-1 next contribute to the activation of PR transcriptional activity itself, which finally contributes to MPA-induced cell proliferation. In another although unrelated scenario, we propose that MPA promoted PR association with a caveolin-1 that is not necessarily phosphorylated, inducing at the same time rapid p-cav phosphorylation via a src-dependent mechanism. Therefore, caveolin-1 is one way or another cooperating with genomic and nongenomic PR action.
We finally evaluated the possibility that caveolin-1 is mutated, thus acting as tumor promoter instead of as tumor suppressor. Mutations in caveolin-1 family genes have been underscored. It was demonstrated that an autosomal dominant mutation resulting in proline to leucine substitution at position 104 (P104L) in the muscle specific caveolin-3 gene causes limb-girdle muscular dystrophy type 1C disease . Analogously, a particular mutation in caveolin-1 gene at the highly conserved codon 132 also caused P-L substitution (P132L) and was found in 16% of human breast cancer cases (Hayashi et al., 2001 ). However, our mutational studies of caveolin-1 gene in C4HD murine breast cancer have not detected any specific mutation either in this specific codon or in the complete region corresponding to the membrane spanning and to the oligomerization domain . It was proposed that P132L mutation of caveolin-1 gene might conduct malignant transformation in breast cancer (Hayashi et al., 2001; Lee et al., 2002) . Nevertheless, our results indicating that caveolin-1 expression is associated with cell proliferation in C4HD cells can not be attributed to P132L mutation of caveolin-1. In line with our own findings demonstrating that caveolin-1 gene was wild type, a recent paper, where a population of 83 Caucasian breast cancer patients was studied (Sloan et al., 2004) , reported no mutation in caveolin-1 gene.
Since first reports proposing a tumor promoting role of caveolin-1 in breast cancer , substantial progress has been made in this field; there is nevertheless no consensus as regards the exact functional role of caveolin-1 as tumor promoter or suppressor, particularly in mammary gland. Thompson and coworkers have consistently demonstrated that caveolin-1 expression was associated with progression of human prostate cancer and with primary and metastatic human breast cancer (Nasu et al., 1998; Thompson et al., 1999; Yang et al., 1999 Yang et al., , 2000 Li et al., 2001; Tahir et al., 2001) . Recently the role of caveolin-1 as a tumor promoting factor in prostate cancer epithelial cells has been definitively addressed in vivo using the TRAMP mice model, which is analogous to human prostate tumors (Williams et al., 2005) . In another report in agreement with this and with our own findings, caveolin-1 was shown not to be expressed in normal breast ductal ephitelia cells obtained from mammary reduction, although it was highly expressed in breast malignant myoephitelial cells and in hyperproliferative myoephitelium (Hurlstone et al., 1999) . On the contrary, in a recent paper by Lisanti and co-workers, the complete loss of caveolin-1 was shown to potentiate tumor development in MMTV-PyMT (mouse mammary tumor virus-Polyoma midle T antigen)/Cav (À/À) mice, resulting in earlier tumor onset, greater tumor multiplicity and increased tumor burden (Williams et al., 2004) . In summary, we have in this study demonstrated that caveolin-1 is a progestin-responsive gene in breast cancer. This, along with the fact that progestin plays a crucial role as a breast cancer promoter, clearly associate caveolin-1 expression with malignant transformation. Further studies need to be conducted to definitively clarify caveolin-1 responsibility on cancer development and progression, and to conscientiously categorize it as a firm target for cancer therapy.
Materials and methods

Animals and tumors
Experiments were carried out in virgin female BALB/c mice raised at the Institute of Biology and Experimental Medicine (IBYME) of Buenos Aires. All animal studies were conducted in accordance with the highest standards of animal care as outlined in the NIH guide for the Care and Use of Laboratory Animals, and were approved by the IBYME Animal Research Committee. Hormone-dependent ductal tumor line C4HD was originated in mice treated with 40 mg MPA every 3 months for 1 year, and has been maintained by serial transplantation in animals treated with 40 mg s.c. MPA depot in the opposite flank to tumor inoculum (Elizalde et al., 1998; Balana et al., 1999 Balana et al., , 2001 ). To generate C4HD tumor growing in MPAuntreated mice, MPA depot was removed by surgery 2 weeks before the tumor was excised. C4HD tumor line is of ductal origin and expresses PR and ER (Elizalde et al., 1998; Balana et al., 1999 Balana et al., , 2001 . Its hormone independent counterpart, C4HI, developed from C4HD tumors growing in mice that were not treated with MPA, approximately a year after the inoculum and has been maintained by serial transplantation in MPA-untreated female mice. C4HI is of ductal origin and retains PR and ER expression. For in vitro experiments, we carried out primary cultures of epithelial cells from C4HD tumors growing in MPA-treated mice as previously described (Elizalde et al., 1998; Balana et al., 1999 Balana et al., , 2001 Labriola et al., 2003) .
RNA and DNA isolation Total RNA was prepared from C4HD tumors from MPAtreated and untreated mice using Trizol Reagent (Life Technologies Inc., Rockville, MD, USA) according to manufacturer's directions. Both population of RNA were converted into cDNA using the SMART PCR cDNA synthesis kit (Clontech Laboratories, Palo Alto, CA, USA). Genomic DNA for mutational analysis was extracted from MPA-treated C4HD tumor samples, MPA-treated culture cells and spleen lymphocytes using DNeasy Qiagen DNA isolation kit (Qiagen, Hilden, Germany) according to manufacturer's instructions.
Suppressive subtractive hybridization cDNA subtraction was carried out using the PCR Select kit from Clontech. Protocol was followed as the manufacturer recommended. Briefly, tester (MPA-treated population) cDNA was subdivided into two groups, with a different adaptor ligated to each. Two hybridizations were performed. In the first, excess driver cDNA (reference population) was separately added to each adaptor-ligated tester cDNA, heat denatured and allowed to anneal, generating a hybrid between tester and driver cDNA. In the second hybridization, the two primary hybridization samples were mixed without denaturation. The remaining single-stranded adaptor-ligated tester formed cDNA hybrids bearing both types of adaptors. PCR amplification was then performed allowing only the tester cDNA molecules having both types of adaptors to be exponentially amplified. PCR products were purified and ligated to a vector. After transformation, D500 colonies were picked in two sets of grid-plates. Total labeled cDNA from the two original populations (MPA-treated and untreated tumors) was prepared and each set was hybridized with a cDNA probe, tester or driver. Spots were then compared to isolate colonies of differentially expressed genes, and inserts were amplified using specifically designed primers.
DNA sequencing and computer analysis Minipreparations (Promega minipreparation kit) of plasmid vectors isolated from colonies of differentially expressed genes were sequenced and BLAST (Basic Local Alignment Search Tool) was used to search sequence similarity. For mutational screening analysis forward cav-1 (5 0 -GCT CCT TCT TTC TTT CAG ATT GAC-3 0 ) and reverse cav-1 (5 0 -TCT CTT TCT GCG TGC TGA TG-3 0 ) PCR primers were designed to specifically amplify caveolin-1 sequences. PCR products were purified using GFX PCR DNA and Gel Band Purification Kit (GE Healthcare, Fairfield, CT, USA) and sequenced using the Big Dye Terminator Cycle sequencing kit with AmpliTaq DNA polymerase (Applied Biosystems, Foster City, CA, USA) in the ABI Prism 3100 DNA sequencer (Applied Biosystems). Nucleotide sequences were analysed using CHROMAS version 2.31 and BLAST.
Northern blot analysis
Forty mg of total RNA from MPA-treated and untreated C4HD, from C4HI tumors and from normal liver were loaded onto a 1% formaldehyde-agarose gel, electrophoresed and transferred to a nylon membrane. The amplified cDNA insert corresponding to caveolin-1 was random-labeled using [ 32 P] dCTP Random Primed DNA Labeling Kit (Boehringer, Mannheim, Germany) to be used as probe. Membranes were hybridized with caveolin-1 probe to confirm MPA upregulation of mRNA expression. Northern blot normalization was performed by incubating the filter with [
32 P]-labeled GAPDH probe.
Cell cultures and proliferation assays Primary cultures of epithelial cells from C4HD tumors growing in MPA-treated mice were performed as previously described (Elizalde et al., 1998; Balana et al., 1999 Balana et al., , 2001 Labriola et al., 2003) . Epithelial cells were plated in culture flasks with DMEM/F12 (without phenol red, with 50 mg/l of gentamicin sulfate) þ 10% fetal calf serum (FCS, Gen S.A., Buenos Aires, Argentina) for 24-48 h. After 48 h incubation in DMEM/F12 þ 10 nM MPA þ 2.5% ChFCS cells were trypsinized, harvested and seeded in a 96-well microtiter plate, and allowed to attach for 24 h to perform a proliferation assay. C4HD cells were incubated in fresh media þ 0.1% ChFCS in the presence of 10 nM MPA or 10 nM þ the indicated concentrations of either antisense oligodeoxinucleotide (ASODN) (5 0 TTTGCCCCCAGACAT-3 0 ) complimentary to the 15-base initiation sequence of mouse caveolin-1 mRNA (Cho et al., 2003) or scramble oligodeoxinucleotide (SODN) (5 0 -CATGGCCTACTCACT-3 0 ) as control (Sigma). In each treatment, after 24 h incubation, 50% of media was replaced by fresh media, and cells were incubated for another 24 h in the presence of 0.8 mC i ( 3 H)-thymidine (NEN, Dupont, Boston, MA, USA; specific activity: 70-90 C i /mmol). Cells were then trypsinized and harvested. Assays were performed in octuplicate. Differences between control and experimental groups were analysed by ANOVA followed by Tukey t-test between groups. T47D cells were obtained from American Type Culture Collection. Human PR null T47D-Y cells were a generous gift from K Horwitz (University of Colorado Health Sciences Center, Denver, CO, USA) (Lange et al., 1998) . Mouse metastatic mammary tumor line LM3, which lacks PR expression, was obtained as described before (Puricelli et al., 2002) .
Preparation of protein lysates from tumors and cells
Tumors excised from MPA-treated or untreated mice and C4HD treated-cells were lyses (on ice) in buffer containing 10 mM Tris (pH 8), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.5% deoxicholic acid, 0.05% SDS, 1 mM phenylmethilsulfonylfluoride (PMSF), 10 mg/ml leupeptin, 5 mg/ml pepstatin, 5 mg/ml aprotinin, 1 mmol/l sodium orthovanadate, 5 mM NaF, 20 mM sodioum molybdate, 5 mg/ml spermin and 5 mg/ml spermidin. Primary cultures of epithelial cells from C4HD tumors growing in DMEM/F12 þ 10 nM MPA were cultured for 48 h in 0.1% ChFCS and then subjected to the different treatments. To block caveolin-1 expression, C4HD cells were incubated with the ASODN and SODN as described above. To block p42/44 MAPK and PI-3K activation, U0126 (Cell Signaling, Beverly, MA, USA) (1, 5 and 10 mM dissolved in dimethyl sulfoxide, (DMSO)) and LY294002 (Sigma) (1, 2 and 4 mM dissolved in DMSO) were added respectively to cells 90 min before the 48 h incubation with 10 nM MPA. For caveolin-1 phosphorylation experiments, C4HD epithelial cells growing in 0.1% ChFCS were treated with 10 nM MPA for 2, 10, 15 and 30 min, or were treated with 10 nM RU486 before MPA stimulation or remained untreated. To block c-Src activation, 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo [3,4-d] pyrimidine (PP2, Cell Signaling, 10 mM, dissolved in DMSO 1:2000) was added to cells 90 min before short-term incubation with 10 nM MPA. Controls were performed in order to verify that DMSO did not modify MPA-modulated cSrc tyrosine phosphorylation or cell viability. After treatments, cells were washed on ice with PBS and lysed in the same buffer as described for tumors. Lysates were centrifuged at 41C for 30 min at 18 000 g and protein content in the supernatant was determined using a Bio-Rad kit (Hercules, CA, USA).
Conditioned media
Conditioned media from C4HD epithelial cells growing in 0.1% ChFCS or in 0.1% ChFCS þ 10 nM MPA for 24 or 48 h were collected. After centrifugation to remove debris, first at 1000 g and then at 100 000 g, conditioned media were concentrated approximately 150 Â using Centricon Centrifugal Filter Devices with a MY-10 membrane (Micon, Millipore, Bedford, MA, USA). Concentrated conditioned media were solubilized in sample buffer and immunoblots were performed as described below.
Immunoblotting
Protein were solubilized in sample buffer (60 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 0.7 mol/l 2b-mercaptoethanol and 0.01% bromophenol blue) and subjected to SDS-PAGE. Proteins were electroblotted onto nitrocellulose. Membranes were immunoblotted with the following antibodies: caveolin-1 (clone 2297) and phospho-caveolin Y14 (clone 56) (BD Biosciences Pharmingen, San Diego, CA, USA), hPR Ab-7 and actin pan Ab-5 (clone ACTN05) from Neomarkers (Freemont, CA, USA), anti-caveolin-1 (N-20), anti-total p42/ p44 MAPK (C-14), phospho-p42/p44 MAPK (E-4) and Src (N-16) antibody from Santa Cruz Biotechnology (Santa Cruz, CA, USA), Phospho-caveolin-1 (Tyr-14), Akt, phospho-Akt (Ser 473) and anti phospho-Src Tyr 416 from Cell Signaling (Beverly, MA, USA). After washing, membranes were incubated with HRP-conjugated secondary antibody (Vector Laboratories, Burlingame, CA, USA). Enhanced chemiluminescence (ECL) was performed according to manufacturer's instructions (Amersham).
Transient transfections
To investigate MPA capacity to induce the transcriptional activation of caveolin-1 promoter, C4HD and T47D cells were transiently transfected with 0.5 or 2 mg, respectively, of a luciferase reporter vector PGL-3 containing a 0.72 Kb mouse caveolin promoter sequence (PGL3-mcav-1-Luc) or an equal quantity of a promoter-less PGL3-basic vector (Promega, Madison WI, USA). PGL-3 vectors were kindly provided by Dr T Thompson (Baylor college of Medicine). T47D-Y and LM3 PR null cells were transfected with 0.5 and 2 mg PGL3-mcav-1-Luc and 40 ng of hPRB (a generous gift from Dr K Horwitz) or with the empty pSG5 plasmid. Fugene 6 transfection reagent (Roche Biochemicals, IN, USA) was used according to manufacturer's instructions. Cells were left untreated growing in 0.1% ChFCS or were treated for 48 h (for C4HD cells) or 24 h (T47D, T47D-Y and LM3 cells) with 10 nM MPA, 10 nM MPA þ 10 nM RU486 or LY294002 (10 mM) or U0126 (4 mM). They were then washed once with PBS, harvested and lysed in 1 Â reporter buffer (Promega) using one freeze-thaw cycle. To evaluate the effect of blocking caveolin-1 expression on PR transcriptional activation, C4HD and LM3 cells were transfected with 2 and 0.5 mg, respectively, of a MMTV-Luc reporter vector, treated with 2 mM ASODN or SODN to caveolin-1, stimulated for 48 h with 10 nM MPA, and harvested as described above. LM3 cells were cotransfected with hPRB as described above. To evaluate the effect of caveolin-1 expression on PR transcriptional activation, T47D cells were transfected with 0.5 mg/well of a caveolin-1 expression vector: m-cav1-pcDNA3 (kindly provided by Dr M Liscovitch) and with 0.5 mg of MMTV-Luc reporter vector as described. Cells were transfected with an equal quantity of Luc-promoter-less vector. In every case cells were cotransfected with 1 mg of a b-galactosidase expression plasmid CMVb-gal (Clontech, Palo Alto, CA, USA) used to correct variations in transfection efficiency. Luciferase activities were measured on a 20/20 n luminometer (TurnerBiosystem, Sunnyvale, CA, USA). Protein concentrations were determined using a Bio-Rad kit (Hercules, CA, USA). Luciferase results were calculated as the ratio of luciferase activity per unit of b-Gal activity. Duplicate samples were analysed for each data point.
In vitro cold phosphorylation assay To study capacity of endogenous Src to phosphorylate caveolin-1, C4HD cells growing in 0.1% ChFCS were treated with MPA for 5 min or preincubated before MPA stimulation for 90 min with the selective Src family kinase inhibitor PP2 (10 mM). Cells were lysed in kinase lysis buffer (20 mM HEPES pH 7.5, 10 mM EGTA, 1% NP-40, 2.5 mM MgCl 2 ) and Src was immunoprecipitated from 500 mg protein extracts from each treatment using an anti-Src antibody. Unphosphorylated caveolin-1 was as well immunoprecipitated from 500 mg protein extract from C4HD cells growing in 0.1%ChFCS. The immunoprecipitated caveolin-1 was then subjected to an in vitro phosphorylation assay with Src immunoprecipitated from each treatment. In brief, caveolin-1 and Src immunoprecipitated were washed once with PBS containing 1% NP-40, 2 mM NaVO 4 , once with 100 mM Tris (pH 7.5), 0.5 M LiCl and then three times with kinase reaction buffer (12.5 mM morpholinepropaneusulfonic acid (pH 7.5), 7.5 MgCl 2 , 0.5 mM EGTA, 12.5 mM b-glycerophosphate, 0.5 mM NaF, 0.5 mM Na 3 VO 4 ). The kinase reaction was performed by incubating Src immunocomplex with equal amount of immunoprecipitated caveolin-1 as the substrate in 30 ml of kinase buffer containing 3.3 mM DTT and 100 mM unlabeled ATP for 30 min at 301C. Proteins were separated by electrophoresis, gels were transferred onto nitrocellulose and in the lower part of the membranes immunoblots were performed with the antiphospho caveolin-1 Tyr 14 antibody. The filter was stripped and reprobed with an anti caveolin-1 antibody. The upper part of the filter was revealed with an anti-phospho Src antibody. The filter was stripped and hybridized with an antibody antitotal Src. As a control of specificity 500 mg protein extract from C4HD cells treated 5 min with MPA were immunoprecipitated with 2 mg rabbit IgG and subjected to the same in vitro phosphorylation protocol.
Caveolin-1 and PR coimmunoprecipitation
To perform caveolin-1 and PR coimmunoprecipitation, cell lysates (500 mg protein) from C4HD cells treated as described were precleared with protein A-agarose for caveolin-1 immunoprecipitates or with protein G-agarose for PR immunoprecipitates (both from Sigma). Two mg of the anti-caveolin-1 antibody (N-20, Santa Cruz Biotechnology) and 2 mg of the anti-hPR antibody were used in each immunoprecipitation, which was rocked for 2 h at 41C. As a control of specificity, immunoprecipitation was also performed with 2 mg of a rabbit or a mouse IgG (Sigma). Thereafter, the immunocomplexes were captured by adding protein A-Agarose or protein-G-Agarose and rocked for an additional hour. Agarose beads were washed three times with lysis buffer, then boiled for 10 min in sample buffer and subjected to SDS-PAGE. Proteins were electroblotted onto nitrocellulose and filters were probed with either anti-caveolin-1 antibody or anti-PR-antibody, and detected as described above.
Immunofluorescence and confocal microscopy C4HD cells grown on glass coverslips were incubated in 0.1%. ChFCS with 10 nM MPA for 5 or 10 min or left untreated. Cells were fixed and permeabilized in ice cold methanol and were then blocked with PBS 1% BSA at room temperature. Caveolin-1 was detected with a rabbit polyclonal antibody dilution 1:500 (N-20, Santa Cruz) followed by incubation with a goat anti-rabbit IgG-Alexa 488 (Molecular Probes, Eugene, OR, USA) secondary antibody. PR was simultaneously detected with a mouse monoclonal antibody dilution 1:100 (Ab-7 Neomarker) followed by incubation with a Rhodamineconjugated anti-mouse secondary antibody (Jackson Laboratories). Control experiments demonstrated no cross reactivity between anti-mouse secondary antibody and rabbit primary antibody nor vice versa, nor was there any detectable staining with secondary antibodies only. Images were obtained in a Carl Zeiss LSM 5 Pascal at Â 100 magnification.
PCR-RFLP Analysis
A mismatch (5 0 -TTC CTG CAC ATC TGG GCG GTG GTA-3 0 ) primer was designed to generate a KpN-1 restriction site after amplifying a caveolin-1 gene fragment together with the reverse primer described above. PCR product was digested at 371C ON with KpN-1 restriction endonuclease. The digested DNAs were electrophoresed in 12% polyacrylamide gel before UV-photos.
